

Press Release

Kraig Biocraft Laboratories, Inc. Announces Patent Filing on Human Diagnostics Technology

- New Diagnostics Platform Incorporating Antigen Fused Polymers-

LANSING, MI – April 10, 2008 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today that a provisional patent application describing a platform for antigen presentation and antibody test kits has been filed listing Dr. Malcolm Fraser, a member of Kraig's Scientific Advisory Board, as the named inventor.

The patent application was filed earlier this year by the University of Notre Dame, where Dr. Fraser heads the University's Laboratory of Molecular Virology.

"The invention describes engineered polymers which incorporate diagnostic antigens," explained Dr. Malcolm Fraser. "The genetically fused polymers can potentially be fashioned into a number of different diagnostic test platforms including serum (blood), salivary, and urine based diagnostics. One of the advantages of a polymer based diagnostic platform is its ability to incorporate multiple antigens into a final product simply by weaving the polymers," Fraser continued. "The result would be a diagnostic tool which could simultaneously screen for several diseases or for other important parameters."

This is the second patent application of 2008 which was made pursuant to Kraig's sponsored research program at the University of Notre Dame and which is subject to Kraig's intellectual property agreement with the University. That agreement provides for exclusive licensing rights for Kraig sponsored research. It is the first such patent application made pursuant to that program relating to human health.

"This ground breaking technology advances Kraig into the growing field of human and animal diagnostics," said company CEO Kim Thompson. "The tremendous potential of genetically fused polymers for diagnostics can not be ignored," continued Thompson. "Our announcement is a big step toward fulfilling the promise of genetically engineered fibers for diagnostics and human health."

For more information on Kraig Biocraft Laboratories please visit the Company's web site: www.KraigLabs.com

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "forecasts," "estimates", "develops", "researching" "research," "goal," "potential," "could" or other words or phrases of similar import. Similarly,

statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:

Kraig Biocraft Laboratories, Inc.

Kim Thompson CEO

(517) 336-0807

info@KraigLabs.com